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Abstract 
Background: We assessed the expression of methylation-related proteins 5-meC, DNMT1, and ISL-1 in breast cancer 
and evaluated their relationship to clinicopathological factors.
Methods: Immunohistochemical staining for ER, PR, HER-2, Ki-67, 5-meC, DNMT1, and ISL-1 were performed on 348 
breast cancer samples in tissue microarray. Samples were subgrouped into luminal A, luminal B, HER-2, or triple-nega-
tive breast cancer (TNBC) according to immunohistochemical staining for ER, PR, HER-2, and Ki-67. The tumor stroma 
was histologically subtyped into desmoplastic, sclerotic, normal-like, or inflammatory type.
Results: Tumor expression of DNMT1 differed by molecular subtype: it was higher in TNBC and lower in luminal A 
(p < 0.001) samples. DNMT1 expression was also related to higher histologic grade, ER negativity, PR negativity, and 
higher Ki-67 LI (p < 0.001). In western blot, protein expressions of DNMT1 and ISL-1 were higher in TNBC and relatively 
lower in the remaining subtypes. High tumor expression of DNMT1 was associated with shorter OS in univariate 
analysis (p = 0.041). DNMT1 and 5-meC were differentially expressed by stromal phenotype: 5-meC was higher in 
normal-like type and lower in sclerotic type (p = 0.049); DNMT1 was higher in inflammatory and lower in sclerotic 
type (p < 0.001).
Conclusions: Tumor expression of DNMT1 in breast cancer differed by molecular subtype and stromal histological 
type. DNMT1 was highly expressed in TNBC and in breast cancer with inflammatory stromal type.
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Background
One of the most important features differentiating cancer 
cells from normal cells is insensitivity to growth inhibi-
tory signals. This insensitivity mostly occurs through 
the inhibition of tumor suppressor genes [1] by DNA 
hypermethylation. DNA hypermethylation is initiated 
by DNA methyltransferases (DNMTs) [2]. Genes for 
the DNMTs identified to date are DNMT1, DNMT2, 
DNMT3A, and DNMT3B. DNMT1 is a key maintenance 
methyltransferase and is the most common methyltrans-
ferase in humans. Molecules associated with DNMT1 
are 5-methylcytosine (5-MeC) and insulin gene enhancer 
binding protein-1 (ISL-1). DNA methylation occurs when 
a methyl group is added to the 5′ position of the cytosine 
ring in CpG dinucleotides, yielding 5-MeC; thus, 5-MeC 
is the end product of DNA methylation. ISL-1 is a direct 
target of DNMT1 in breast cancer [3]. Previous studies of 
epigenetic methylation-related proteins in breast cancer 
found that expression of DNMT1 and DNMT3a is higher 
in breast cancer than in benign lesions and the expression 
is related to breast cancer prognosis [4]. However, breast 
cancers are heterogeneous tumors with diverse clinical, 
histological, and molecular features; thus, breast cancer 
is subgrouped into luminal A, luminal B, HER-2, normal 
breast-like, and basal-like types by gene profiling analysis 
[5, 6]. These molecular subgroups have different molecu-
lar, histological, and clinical features and differ in treat-
ment response and prognosis. Breast cancer subtypes 
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are expected to have differential expression of epigenetic 
methylation-related proteins, but studies on this topic 
have not yet been reported. We assessed the expression 
of methylation-related proteins 5-meC, DNMT1, and 
ISL-1 in breast cancer and evaluated their relationships 
with clinicopathological factors.
Methods
Patient selection and histological evaluation
Patients diagnosed with invasive ductal carcinoma, NOS, 
at Severance Hospital from January 2000 to December 
2006 were included. Patients who received preoperative 
chemotherapy or hormonal therapy were excluded. This 
study was approved by the Institutional Review Board of 
Yonsei University Severance Hospital and was exempt 
from informed consent from patients. Hematoxylin and 
eosin (H&E)-stained slides of all cases were reviewed 
by a breast pathologist (Koo JS). Histological grade was 
assessed using the Nottingham grading system [7]. Clin-
icopathological parameters evaluated were patient age at 
initial diagnosis, lymph node metastasis, tumor recur-
rence, distant metastasis, and patient survival. Tumor 
stroma were subgrouped as: (1) desmoplastic type for 
tumor stroma with cellular fibroblast/myofibroblast pro-
liferation; (2) sclerotic type for tumor stroma of fibrotic 
collagenous components with little cellular component; 
(3) normal-like type for stroma with no stromal reac-
tion around tumor cells or for normal breast stroma; and 
(4) inflammatory type for tumor stroma composed of 
inflammatory cells such as lymphocytes.
Tissue microarrays
A representative area showing the tumor and tumor stroma 
was selected on an H&E-stained slide and a correspond-
ing spot was marked on the surface of the paraffin block. 
Using a biopsy needle, the selected area was punched out 
and a 3-mm tissue core was transferred to a 6 × 5 recipient 
block. Two tissue cores of invasive tumor were extracted to 
minimize extraction bias. Each tissue core was assigned a 
unique tissue microarray location number linked to a data-
base containing clinicopathological data.
Immunohistochemistry
Antibodies used for immunohistochemistry are listed 
in Table  1. Immunohistochemistry used formalin-fixed, 
paraffin-embedded 5-μm tissue sections obtained with a 
microtome, transferred onto adhesive slides, and dried at 
62 °C for 30 min. After incubation with primary antibod-
ies, immunodetection was performed with biotinylated 
anti-mouse immunoglobulin followed by peroxidase-
labeled streptavidin using a labeled streptavidin–biotin 
kit with 3,3′-diaminobenzidine chromogen as the sub-
strate. The primary antibody incubation step was omitted 
in the negative control. Positive control tissue was used 
as per the manufacturer’s recommendation. Slides were 
counterstained with Harris hematoxylin.
Interpretation of immunohistochemical staining
Immunohistochemical markers were assessed by light 
microscopy. A cut-off value of 1  % or more positively 
stained nuclei was used to define estrogen receptor (ER) 
and progesterone receptor (PR) positivity [8]. HER-2 
staining was analyzed according to the American soci-
ety of clinical oncology-college of American pathologists 
guidelines using the following categories: 0, no immu-
nostaining; 1+, weak, incomplete membranous staining 
of less than 10 % tumor cells; 2+, complete membranous 
staining, either uniform or weak in at least 10 % of tumor 
cells; and 3+, uniform, intense membranous staining in 
at least 30 % of tumor cells [9]. HER-2 immunostaining 
was considered positive when strong (3+) membranous 
staining was observed; samples scored as 0 to 1+  were 
regarded as negative. Samples showing 2+  HER-2 
expression were evaluated for HER-2 amplification by 
fluorescent in situ hybridization (FISH).
Immunohistochemical staining for 5-meC, DNMT1, 
and ISL1 was assessed semiquantitatively by light micros-
copy [10]. Staining results in malignant cells and stromal 
cells were assessed as 0, negative or weak immunostain-
ing in  <1  % of the tumor/stroma; 1, focal expression in 
1–10 % of tumor/stroma; 2, positive in 11–50 % of tumor/
stroma; and 3, positive in 51–100  % of tumor/stroma. 
This evaluation was applied to all areas of the tumor in 
all samples; grade 0 was negative and grades higher than 
1 were positive. Positive results were further classified as 
low (grades 1 and 2) and high (grade 3).
Tumor phenotype classification
We classified breast cancer phenotypes according to 
immunohistochemical results for ER, PR, HER-2, and 
Table 1 Source, clone, and dilution of antibodies
Antibody Company Clone Dilution
DNA methylation-related proteins
 DNMT1 Abcam, Cambridge, UK 2B5 1:200
 5-meC Abcam, Cambridge, UK 33D3 1:200
 ISL-1 Abcam, Cambridge, UK Polyclonal 1:200
Molecular subtype-related proteins
 ER Thermo Scientific, San Diego,  
CA, USA
SP1 1:100
 PR DAKO, Glostrup, Denmark PgR 1:50
 HER-2 DAKO, Glostrup, Denmark Polyclonal 1:1500
 Ki-67 Abcam, Cambridge, UK MIB 1:1000
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Ki-67 and FISH results for HER-2 [11]: luminal A type, 
ER or/and PR positive, HER-2 negative, and Ki-67 
LI <14 %; luminal B type (HER-2 negative), ER or/and PR 
positive, HER-2 negative and Ki-67 LI ≥14 %; luminal B 
type (HER-2 positive), ER or/and PR positive and HER-2 
overexpressed or/and amplified; HER-2 overexpression 
type, ER and PR negative and HER-2 overexpressed or/
and amplified; and TNBC type, ER, PR, and HER-2 
negative.
Laser microdissection, protein extraction from FFPE tissues 
and Western blot
To acquire tumor, laser microdissection was performed 
with hematoxylin stained uncovered slides generated by 
FFPE blocks (LMD 6500, Leica, Wetzlar,Germany). Five 
cases per each molecular subtype of breast cancer were 
miscrodissected. Protein extractions from formalin-fixed, 
paraffin-embedded (FFPE) tissues were performed using 
the Qproteome FFPE tissue kit (Qiagen, Hilden, Ger-
many). Briefly, three sections from the same block were 
deparaffinized in xylene and rehydrated in graded series 
of alcohol. The tissues were mixed with FFPE extraction 
buffer (EXB), incubated at 100 °C for 20 min and at 80 °C 
for 2  h with agitation at 750  rpm, and then centrifuged 
for 15 min at 14,000×g at 4 °C. The supernatant contain-
ing the extracted proteins were determined by the Brad-
ford assay (Bio-Rad Laboratories, Hercules, CA). An 
equal amount of protein from each sample extract was 
separated on SDS-PAGE gels and blotted onto nitrocel-
lulose membranes (Bio-Rad). Western blotting was per-
formed with primary antibodies against Dnmt 1, Islet 1, 
and actin (Abcam, Cambridge, UK), and specific bands 
were detected using the enhanced chemiluminescence kit 
(GE Healthcare Life Sciences, Little Chalfont, UK).
Statistical analysis
Data were analyzed using SPSS for Windows, Version 
12.0 (SPSS Inc., Chicago, IL, USA). For determination of 
statistical significance, Student’s t test and Fisher’s exact 
test were used for continuous and categorical variables, 
respectively. To analyze data with multiple comparisons, 
a corrected p-value with application of the Bonferroni 
multiple comparison procedure was used. Statistical 
significance was set at p  <  0.05. Kaplan–Meier survival 
curves and log-rank statistics were used to evaluate time 
to tumor recurrence and overall survival. Multivariate 
regression analysis used the Cox proportional hazards 
model.
Results
Basal characteristics of breast cancer
Among the 348 breast cancer samples in this study, 162 
(42.8 %) were luminal A, 84 (23.7 %) were luminal B, 27 
(9.0  %) were HER-2 type, and 75 (24.5  %) were TNBC. 
Upon evaluation of clinicopathologic parameters, his-
tologic grade, KI-67 LI, and stromal phenotype were 
different according to the molecular subtype with statis-
tical significance (p < 0.001). TNBC was associated with 
higher histological grade and higher Ki-67 LI than other 
subtypes (Table  2). Luminal B demonstrated a higher 
percentage of desmoplastic stromal type than other sub-
types, whereas TNBC demonstrated a higher percentage 
of inflammatory type.
Expression of epigenetic methylation‑related proteins 
in breast cancer
The epigenetic methylation-related proteins 5-meC 
and DNMT1 were expressed in both malignant cells 
and stromal cells, and ISL-1 was expressed only in 
the malignant cells. Expression analysis of epigenetic 
methylation-related proteins according to the molecu-
lar subtypes revealed that the expression of DNMT1 in 
malignant cells differs by molecular subtype (p < 0.001): 
it was higher in TNBC and lower in luminal A (Table 3 
and Fig.  1). Expression of DNMT1 in stromal cells was 
apparent in TNBC only. Meanwhile, expression analysis 
of epigenetic methylation-related proteins according to 
the stromal phenotypes demonstrated that the expres-
sions of 5-meC and DNMT1 in malignant cells differ by 
stromal phenotype (p  =  0.049, and p  <  0.001, respec-
tively): 5-meC expression in malignant cells was highly 
expressed in normal-like type, with lower expression in 
sclerotic type. Expression of DNMT1 in malignant cells 
was higher in inflammatory type and lower in sclerotic 
type (Table 4 and Fig. 2). Fourteen cases (4 %) disclosed 
low positive results for 5-meC in the stromal component, 
in which spindle cells with a negative reaction to 5-meC 
were seen (Fig. 3). Only two cases (0.6 %) had a positive 
reaction to DNMT1 in the stromal cells.
Differences in clinicopathologic factors according to the 
expression status of epigenetic methylation‑related 
proteins
When clinicopathologic parameters were evaluated 
according to the expression status of epigenetic methyla-
tion-related proteins, expression of DNMT1 in malignant 
cells was associated with higher histological grade, ER 
negativity, PR negativity, and higher Ki-67 LI (p < 0.001) 
(Fig. 4).
Impact of epigenetic methylation‑related protein 
expression in breast cancer on patient prognosis
Univariate analysis of the impact of epigenetic methyla-
tion-related protein expression on breast cancer patient 
prognosis showed that high expression of DNMT1 in 
malignant cells correlated with shorter OS (p  =  0.041) 
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(Table  5 and Fig.  5a); however, the association was not 
significant in multivariate Cox analysis (Table  6). Uni-
variate analysis of the impact of epigenetic methylation-
related protein expression by stromal phenotype on 
patient prognosis showed that high expression of DNM-
T1in malignant cells tended to be associated with shorter 
OS in sclerotic type (p = 0.052, Fig. 5b).
Western blot analysis of the epigenetic methylation‑related 
protein in breast cancer according to the molecular subtype
Western blot analysis was performed to confirm the 
expression of epigenetic methylation-related protein 
according to the breast cancer molecular subtypes. Pro-
tein expressions of DNMT1 and ISL-1 were higher in 
TNBC and relatively lower in the remaining subtypes 
(Fig. 6).
Discussion
We assessed the expression status of epigenetic methyl-
ation-related proteins in breast cancer. Tumor expres-
sion of DNMT1 differed with breast cancer molecular 
subtype. Our results identified high tumor expression of 
DNMT1 in TNBC and low tumor expression of DNMT 
1 in luminal A type, concordant with a previous study in 
Table 2 Clinicopathological characteristics of patients by breast cancer molecular subtype
TNBC triple negative breast cancer
Parameter Total (n = 348)  
(%)
Luminal A (n = 162)  
(%)
Luminal B (n = 84)  
(%)
HER‑2 (n = 27)  
(%)
TNBC (n = 75)  
(%)
P value
Age (years)
 ≤50 202 (58.0) 94 (58.0) 55 (65.5) 13 (48.1) 40 (53.3) 0.299
 >50 146 (46.7) 68 (42.0) 29 (34.5) 14 (51.9) 35 (46.7)
Histological grade
 I/II 242 (69.5) 147 (90.7) 53 (63.1) 12 (44.4) 30 (40.0) <0.001
 III 106 (30.5) 15 (9.3) 31 (36.9) 15 (55.6) 45 (60.0)
Tumor stage
 T1 182 (52.3) 96 (59.3) 42 (50.0) 13 (48.1) 31 (41.3) 0.068
 T2/T3 166 (47.7) 66 (40.7) 42 (50.0) 14 (51.9) 44 (58.7)
Nodal metastasis
 Absent 208 (59.8) 94 (58.0) 48 (57.1) 17 (63.0) 49 (65.3) 0.676
 Present 140 (40.2) 68 (42.0) 36 (42.9) 10 (37.0) 26 (34.7)
Estrogen-receptor status
 Negative 107 (30.7) 2 (1.2) 3 (3.6) 27 (100.0) 75 (100.0) <0.001
 Positive 241 (69.3) 160 (98.8) 81 (96.4) 0 (0.0) 0 (0.0)
Progesterone-receptor status
 Negative 149 (42.8) 20 (12.3) 27 (32.1) 27 (100.0) 75 (100.0) <0.001
 Positive 199 (57.2) 142 (87.7) 57 (67.9) 0 (0.0) 0 (0.0)
HER-2 status
 Negative 280 (80.5) 162 (100.0) 43 (51.2) 0 (0.0) 75 (100.0) <0.001
 Positive 68 (19.5) 0 (0.0) 41 (48.8) 27 (100.0) 0 (0.0)
Ki-67 LI (%)
 ≤14 213 (61.2) 162 (100.0) 24 (28.6) 13 (48.1) 14 (18.7) <0.001
 >14 135 (38.8) 0 (0.0) 60 (71.4) 14 (51.9) 61 (81.3)
Stromal phenotype
 Desmoplastic type 97 (27.9) 42 (25.9) 34 (40.5) 6 (22.2) 15 (20.0) <0.001
 Inflammatory type 30 (8.6) 3 (1.9) 4 (4.8) 3 (11.1) 20 (26.7)
 Normal-like type 16 (4.6) 7 (4.3) 4 (4.8) 0 (0.0) 5 (6.7)
 Sclerotic type 205 (58.9) 110 (67.9) 42 (50.0) 18 (66.7) 35 (46.7)
Tumor recurrence 32 (9.2) 10 (6.2) 8 (9.5) 3 (11.1) 11 (14.7) 0.204
No. of patient deaths 35 (10.1) 9 (5.6) 9 (10.7) 4 (14.8) 13 (17.3) 0.033
Duration of clinical 
follow-up (months, 
mean ± SD)
77.0 ± 33.8 78.4 ± 31.9 75.2 ± 33.5 77.7 ± 39.5 75.7 ± 36.3 0.884
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Table 3 Expression of epigenetic methylation-related proteins by breast cancer subtype
Parameter Total  
(n = 348) (%)
Luminal A  
(n = 162) (%)
Luminal B  
(n = 84) (%)
HER‑2  
(n = 27) (%)
TNBC  
(n = 75) (%)
P value
5-meC (T)
 Low 44 (12.6) 27 (16.7) 8 (9.5) 3 (11.1) 6 (8.0) 0.200
 High 304 (87.4) 135 (83.3) 76 (90.5) 24 (88.9) 69 (92.0)
5-meC (S)
 Low 14 (4.0) 7 (4.3) 2 (2.4) 1 (3.7) 4 (5.3) 0.810
 High 334 (96.0) 155 (95.7) 82 (97.6) 26 (96.3) 71 (94.7)
DNMT1 (T)
 Low 316 (90.8) 161 (99.4) 77 (91.7) 24 (88.9) 54 (72.0) <0.001
 High 32 (9.2) 1 (0.6) 7 (8.3) 3 (11.1) 21 (28.0)
DNMT1 (S)
 Negative 346 (99.4) 162 (100.0) 84 (100.0) 27 (100.0) 73 (97.3) 0.062
 Positive 2 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.7)
ISL-1 (T)
 Negative 343 (98.6) 159 (98.1) 84 (100.0) 27 (100.0) 73 (97.3) 0.455
 Positive 5 (1.4) 3 (1.9) 0 (0.0) 0 (0.0) 2 (2.7)
Fig. 1 Expression of epigenetic methylation-related proteins by breast cancer molecular subtype. Expression of DNMT1 in malignant cells is higher 
in TNBC and lower in luminal A. Expression of DNMT1 in stromal cells is apparent in TNBC only
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Table 4 Expression of epigenetic methylation-related proteins by stromal phenotype
Parameter Total  
(n = 348) (%)
Desmoplastic type 
(n = 97) (%)
Inflammatory type 
(n = 30) (%)
Normal‑like type 
(n = 16) (%)
Sclerotic type 
(n = 205) (%)
P value
5-meC (T)
 Low 44 (12.6) 8 (8.2) 2 (6.7) 0 (0.0) 34 (16.6) 0.049
 High 304 (87.4) 89 (91.8) 28 (93.3) 16 (100.0) 171 (83.4)
5-meC (S)
 Low 14 (4.0) 3 (3.1) 1 (3.3) 0 (0.0) 10 (4.9) 0.726
 High 334 (96.0) 94 (96.9) 29 (96.7) 16 (100.0) 195 (95.1)
DNMT1 (T)
 Low 316 (90.8) 88 (90.7) 21 (70.0) 14 (87.5) 193 (94.1) <0.001
 High 32 (9.2) 9 (9.3) 9 (30.0) 2 (12.5) 12 (5.9)
DNMT1 (S)
 Negative 346 (99.4) 97 (100.0) 29 (96.7) 16 (100.0) 204 (99.5) 0.197
 Positive 2 (0.6) 0 (0.0) 1 (3.3) 0 (0.0) 1 (0.5)
ISL-1 (T)
 Negative 343 (98.6) 96 (99.0) 29 (96.7) 16 (100.0) 202 (98.5) 0.775
 Positive 5 (1.4) 1 (1.0) 1 (3.3) 0 (0.0) 3 (1.5)
Fig. 2 Expression of epigenetic methylation-related proteins by breast cancer stromal phenotype. 5-meC expression in malignant cells is highly 
expressed in normal-like type, with lower expression in sclerotic type. In addition, expression of DNMT1 in malignant cells is higher in inflammatory 
type and lower in sclerotic type
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which DNMT1 expression was reported to be increased 
in breast cancer compared to other benign lesions, 
especially in ER-negative breast cancer [4]. DNMT1 
expression in our study was also correlated with ER nega-
tivity and PR negativity. A possible mechanism of higher 
expression of DNMT1 in TNBC might be association 
of TNBC with cancer stem cells. TNBC is highly corre-
lated with cancer stem cell characteristics and DNMT1 
is essential for cancer cell maintenance, resulting in 
high expression of DNMT1 in TNBC [3]. Our results 
showed that the expression of epigenetic methylation-
related proteins differ by stromal phenotype. Tumor 
expression of DNMT1 was higher in inflammatory stro-
mal type samples compared to other subtypes. Previous 
studies reported that IL-6 increases nuclear transloca-
tion of DNMT1 through phosphorylation of the nuclear 
localization sequence [12]. IL-6 is mainly secreted by 
tumor-infiltrating lymphocytes [13] and tumor-associ-
ated macrophages [14], explaining the increased expres-
sion of DNMT1 in the inflammatory stromal subtype. 
These results imply that stromal subtype might affect 
the methylation status of breast cancer. However, further 
study is needed to test this hypothesis.
DNMT1 and 5-meC were expressed in both malig-
nant cells and stromal cells, although with different 
expression status; 5-meC was expressed in the stromal 
cells in 96  %, whereas DNMT1 was expressed in only 
less than 1 %. An important factor in the tumor micro-
environment is cancer-associated fibroblasts (CAFs). 
Epigenetic alteration can occur in CAFs, as seen by dif-
ferences in specific DNA methylation patterns between 
tumor-associated stroma and non-tumor stroma on 
methylation pattern analysis [15, 16]. About 4 % of the 
cases in our study had spindle-shaped stromal cells that 
Fig. 3 Representative images for 5-meC (a, b) and DNMT1 (c, d) in breast cancer stroma (a) tumor cells and tumor stromal cells showing a positive 
reaction to 5-meC, b tumor cells positive for 5-meC, but with spindle cells (arrow) negative to 5-meC within the stroma. c Tumor cells and tumor 
stromal cells were positive for DNMT1; d tumor cells positive to DNMT1, but with negative stromal cells
Page 8 of 11Shin et al. J Transl Med  (2016) 14:87 
were non-immunoreactive to 5-meC. These 5-meC-
negative spindle cells are presumed to be hypomethyl-
ated CAFs, but this possibility needs to be tested with 
further study. The expression of DNMT1 was mostly 
negative in the tumor stroma, compatible with previ-
ous results showing no or low immunohistochemical 
reaction to DNMT1 in the tumor stroma and normal 
stroma [17].
We found an association between high tumor expres-
sion of DNMT1 and shorter OS, concordant with pre-
vious studies in which high expression of DNMT1 was 
associated with poor prognosis in malignant lymphoma 
[10], renal cell carcinoma [18], pancreatic cancer [19], 
and bladder cancer [20]. The clinical significance of this 
result is the possibility of therapy targeting epigenetic 
methylation-related proteins such as DNMT1. Cur-
rently, the possibility of DNMT1 as a new target is 
being explored for many tumors [21–24] and DNMT1 
can be a new target for breast cancer as well. Since the 
expression degree of DNMT1 differs by molecular and 
stromal subtypes, DNMT1 may very well be a new ther-
apeutic target for breast cancer type with high DNMT1 
expression.
Conclusion
In conclusion, DNMT1 is differentially expressed in 
breast cancer according to the molecular and stromal 
subtypes, and it is most highly expressed in TNBC and 
inflammatory stromal types.
Fig. 4 Differences of clinicopathological factors according to the expression of DNMT1 in malignant cells. Expression of DNMT1 in malignant cells is 
associated with higher histological grade, ER negativity, PR negativity, and higher Ki-67 LI
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Table 5 Univariate analysis of the impact of epigenetic methylation-related protein expression on breast cancer patient 
prognosis by log-rank test
Parameter Number of  
patients/recurrence/ 
death
Disease‑free survival Overall survival
Mean survival  
(95 % CI) months
P value Mean survival  
(95 % CI) months
P value
5-meC (T)
 Low 44/2/3 131 (124–138) 0.206 132 (124–141) 0.370
 High 304/30/32 126 (121–130) 127 (123–132)
5-meC (S)
 Low 14/1/1 129 (115–143) 0.709 131 (116–145) 0.659
 High 334/31/34 127 (122–131) 128 (124–132)
DNMT1 (T)
 Low 316/28/29 127 (123–131) 0.348 129 (126–133) 0.041
 High 23/4/6 115 (100–129) 111 (95–128)
DNMT1 (S)
 Negative 346/32/35 N/A N/A N/A N/A
 Positive 2/0/0 N/A N/A
ISL-1 (T)
 Negative 343/32/34 N/A N/A 128 (124–132) 0.436
 Positive 5/0/1 N/A 63 (60–66)
Fig. 5 Overall survival for breast cancer (a) and breast cancer with sclerotic stromal type (b) according to DNMT1 status in malignant cells
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Abbreviations
DNMT: DNA methyltransferase; 5-MeC: 5-methylcytosine; ISL-1: insulin gene 
enhancer binding protein-1, 2; H&E: hematoxylin and eosin; ER: estrogen 
receptor; PR: progesterone receptor.
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Table 6 Multivariate analysis of breast cancer survival
Included parameters Disease‑free survival Overall survival
Hazard ratio 95 % CI P value Hazard ratio 95 % CI P value
T stage
 T1 versus T2–3 2.376 1.064–5.305 0.035 1.714 0.826–3.556 0.148
N stage
 N0 versus N1–3 2.994 1.424–6.296 0.004 2.127 1.061–4.262 0.033
Histologic grade
 I/II versus III 1.214 0.515–2.859 0.658 0.785 0.353–1.747 0.553
ER status
 Negative versus positive 0.544 0.197–1.507 0.242 0.650 0.259–1.632 0.359
PR status
 Negative versus positive 0.768 0.275–2.147 0.615 0.436 0.164–1.158 0.096
HER-2 status
 Negative versus positive 0.967 0.406–2.307 0.940 1.050 0.463–2.381 0.907
Ki-67 LI
 ≤14 versus >14 0.764 0.308–1.899 0.563 0.805 0.340–1.901 0.620
5-meC (T)
 Low versus high 3.117 0.728–13.35 0.126 1.828 0.543–6.155 0.330
5-meC (S)
 Low versus high 1.498 0.201–11.13 0.693 1.515 0.203–11.31 0.686
DNMT1 (T)
 Low versus high 0.937 0.289–3.037 0.913 1.473 0.538–4.036 0.451
DNMT1 (S)
 Negative versus positive N/A N/A N/A N/A N/A N/A
ISL-1 (T)
 Negative versus positive N/A N/A N/A 2.075 0.270–15.96 0.483
Fig. 6 Western blot analysis of DNMT1 and ISL-1 in FFPE breast 
cancer tissue according to the molecular subtype. Protein expressions 
of DNMT1 and ISL-1 are higher in TNBC and relatively lower in the 
remaining subtypes
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